This clinical trial is focused on studying the effects of Simvastatin in preventing recurrent episodes of pancreatitis. Pancreatitis is a condition where the pancreas, an organ that helps with digestion, becomes inflamed. The study aims to see if taking Simvastatin can reduce the number of new pancreatitis episodes in people who have had it before. Simvastatin is a medication commonly used to lower cholesterol levels, and it is being tested here for its potential benefits in pancreatitis.

Participants in the study will be randomly assigned to receive either Simvastatin or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be “triple-blind,” meaning that the participants, the healthcare providers, and the researchers do not know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The treatment period will last for up to 12 months, during which participants will take the medication orally in the form of a film-coated tablet.

The main goal of the study is to compare the number of new pancreatitis episodes between those taking Simvastatin and those taking the placebo. Additionally, the study will look at other factors such as the development of new health issues like diabetes or pancreatic insufficiency, the severity of pancreatitis episodes, and the number of hospital visits due to abdominal pain. The results of this study could provide valuable information on whether Simvastatin can be an effective treatment for preventing recurrent pancreatitis.